Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 752-756

  Yardley, Vanessa ^a   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG USE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030891936     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.752     Document Type: Article

References (43)

1. Aebischer, T., S. F. Moody, and E. Handman. 1993. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 61:220-226.
2. Allen, T. M., C. B. Hansen, and L. S. S. Guo. 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150:9-16.
3. Allen, S., and R. A. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711. In D. T. Hart (ed.), Leishmaniasis. Plenum Publishing Corporation, United Kingdom.
4. Herman, J. D., W. L. Hanson, W. L. Chapman, C. R. Alving, and G. Lopez-Berestein. 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30:847-851.
5. Bolard, J., and A. Vertut-Doi. 1995. Internalization of amphotericin B and other polyene antifungals in mammalian cells: a possible origin of their toxicity, p. 307. In N. H. Georgopapadakou (ed.), Drug transport in antimicrobial and anticancer chemotherapy. Marcel Dekker, Inc., New York, N.Y.
6. Bosque, B., J. Moufqia, Y. Belkaid, J.-H. Colle, V. Leclercq, M. Lebastard, and G. Milon. 1995. Parasite-host relationships: in-situ study of Leishmania spp. in resistant and susceptible mice. Ann. Trop. Med. Parasitol. 89(Suppl. 1): 19-22.
7. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Chemother. 28(Suppl. B):111-118.
8. Davidson, R. N., L. di Martino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, A. Cascio, T. Prestileo, L. Caldera, R. J. Wilkinson, and A. D. M. Bryceson. 1994. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Q. J. Med. 87:75-81.
9. Davidson, R. N., and R. Russo. 1994. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin. Infect. Dis. 19:560. (Letter.)
10. de Marie, S., R. Janknegt, and I. A. J. M. Bakker-Woudenberg. 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907-916.
11. Dietze, R., S. M. S. Fagundes, E. F. Brito, E. P. Milan, T. F. Feitosa, F. A. B. Suassuna, G. Fonschiffrey, G. Ksionski, and J. Dember. 1995. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Trop. Med. Hyg. 89:309-311.
12. Dietze, R., E. P. Milan, J. D. Berman, M. Grogl, A. Falqueto, T. F. Feitosa, K. G. Luz, F. A. B. Suassuna, L. A. C. Marinho, and G. Ksionski. 1993. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. 17:981-986.
13. Edmonds, L. C., L. Davidson, and J. S. Bertino. 1991. Effect of variation in infusion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate. J. Antimicrob. Chemother. 28:919-24.
14. Elhassan, A. M., A. Gaafar, and T. G. Theander. 1994. Antigen-presenting cells in human cutaneous leishmaniasis due to Leishmania major. Clin. Exp. Immunol. 99:445-453.
15. Gokhale, P. C., N. A. Kshirsagar, M. U. Khan, S. K. Pandya, Y. V. Meisheri, C. P. Thakur, and C. B. Choudhury. 1993. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. Trans. R. Soc. Trop. Med. Hyg. 88:288.
16. Gradoni, L., A. Bryceson, and P. Desjeux. 1995. Treatment of Mediterranean visceral leishmaniasis. Bull. W. H. O. 73:191-197.
17. Gradoni, L., R. N. Davidson, S. Orsini, P. Betto, and M. Giambenedetti. 1993. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J. Drug Targ. 1:311-316.
18. Gregoriadis, G. 1991. Overview of liposomes. J. Antimicrob. Chemother. 28(Suppl. B):39-48.
19. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacol. 23:279-291.
20. Jha, T. K., Y. N. Giri, T. K. Singh, and S. Jha. 1995. The use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India. Am. J. Trop. Med. Hyg. 52:536-538.
21. Khoo, S. H., J. Bond, and D. W. Denning. 1994. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 33:203-213.
22. Lasic, D. D., and D. Papahadjopolous. 1995. Liposomes revisited. Science 267:1275-1276.
23. Legrand, P., A. Vertut-Doi, and J. Bolard. 1996. Comparative internalization of different amphotericin B formulations by a macrophage-like cell line. J. Antimicrob. Chemother. 37:519-533.
24. Llanos-Cuentas, A., J. Echevarria, J. Chang, P. Campos, J. Cieza, D. Lentnek, D. Gonzalez, M. Robbins, and R. Williams. 1991. Randomized trial of amphotericin B complex (ABLC) versus Fungizone in patients with mucocutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz 86(Suppl. 1):238.
25. Locksley, R. M., and J. A. Louis. 1992. Immunology of leishmaniasis. Curr. Opin. Immunol. 4:413-418.
26. 4 involvement in cutaneous leishmaniasis: relation with infection status and cytokine production. Parasitology 112:13-19.
27. Mirkovich, A. M., A. Galelli, A. C. Allison, and F. Z. Modabber. 1986. Increased myelopoiesis during Leishmania major infection in mice: generation of "safe targets", a possible way to evade the effector immune system. Clin. Exp. Immunol. 64:1-7.
28. Murray, H. W. 1994. Blood monocytes: differing effector role in experimental visceral versus cutaneous leishmaniasis. Parasitol. Today 10:220-223.
29. New, R. R. C., M. L. Chance, and S. Heath. 1981. The treatment of experimental cutaneous leishmaniasis with liposome-entrapped Pentostam. Parasitology 83:519-527.
30. New, R. R. C., M. L. Chance, and S. Heath. 1981. Antileishmanial activity of amphotericin B and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371-381.
31. Panosian, C. B., M. Barza, F. Szoka, and D. J. Wyler. 1984. Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 25:655-656.
32. Pitt, A., L. S. Mayorga, A. L. Schwartz, and P. D. Stahl. 1992. Transport of phagolysosomal components to an endosomal compartment. J. Biol. Chem. 5:126-132.
33. Proffitt, R. T., A. Satorius, S.-M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B): 49-61.
34. Saha, A. K., T. Mukherjee, and A. Bhaduri. 1986. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 19:195-200.
35. Seaman, J., C. Boer, R. Wilkinson, J. de Jong, E. de Wilde, E. Sondorp, and R. Davidson. 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21:188-193.
36. Thakur, C. P., A. K. Pandey, G. P. Sinha, S. Roy, P. Olliaro, and M. K. Bebehani. 1996. Comparison of regimens of treatment with liposomal amphotericin B (AmBisome) in Indian kala-azar: a randomised study. Trans. R. Soc. Trop. Med. Hyg. 90:319-322.
37. Torre-Cisneros, J., J. L. Prada, J. L. Villanueva, F. Valverde, and P. Sanchez-Guijo. 1994. Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. Clin. Infect. Dis. 18:1024-1025. (Letter.)
38. van Etten, E. W. M., M. Otte-Lambillion, W. van Vianen, M. T. ten Kate, and I. A. J. M. Bakker-Woudenberg. 1995. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chemother. 35:509-519.
39. Vertut-Doï, A., S.-I. Ohnishi, and J. Bolard. 1994. The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob. Agents Chemother. 38:2373-2379.
40. Wasan, K. M., and G. Lopez-Berestein. 1994. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J. Drug Targ. 2:373-380.
41. Wasan, K. M., R. E. Morton, M. G. Rosenblum, and G. Lopez-Berestein. 1994. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein; J. Pharm. Sci. 7:1006-1010.
42. World Health Organization. 1990. Control of the leishmaniases. Report of a WHO Expert Committee. WHO Tech. Rep. Ser. 793:50-55.
43. Wu, N. Z., D. Da, T. L. Rudoll, D. Needham, A. R. Whorton, and M. W. Dewhirst. 1993. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumour tissue. Cancer Res. 53: 3765-3770.